XML 52 R37.htm IDEA: XBRL DOCUMENT
v3.24.1.1.u2

Fair Value Financial Instruments (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Fair Value Disclosures [Line Items] |
Summary of Common Stock Warrants Outstanding | The following table summarizes our common stock warrants outstanding at December 31, 2023 and 2022:
Issue Date |  | December 31, 2023 |  |  | December 31, 2022 |  |  | Exercise Price |  |  | Termination Date |
6/10/2022 |  |  | 4,848,963 |  |  |  | 4,939,515 |  |  | $ | 3.35 |  |  |  | 12/10/2027 |
3/6/2023 |  |  | 3,703,703 |  |  |  | — |  |  | $ | 3.78 |  |  |  | 3/6/2026 |
Various 2020 |  |  | 551,378 |  |  |  | 551,378 |  |  | $ | 3.99 |  |  |  |  | **
12/1/2023 |  |  | 1,411,769 |  |  |  | — |  |  | $ | 4.25 |  |  |  | 12/1/2026 |
8/14/2020 |  |  | — |  |  |  | 131,816 |  |  | $ | 4.67 |  |  |  | 8/14/2023 |
8/25/2020 |  |  | 1,873,622 |  |  |  | 1,873,622 |  |  | $ | 4.75 |  |  |  | 2/25/2024 |
7/19/2019 |  |  | 196,135 |  |  |  | 196,135 |  |  | $ | 5.76 |  |  |  | 7/8/2024 |
12/1/2023 |  |  | 211,569 |  |  |  | — |  |  | $ | 7.09 |  |  |  | 12/1/2026 |
11/2/2018 |  |  | — |  |  |  | 700,000 |  |  | $ | 7.16 |  |  |  | 11/2/2023 |
|  |  | 12,797,139 |  |  |  | 8,392,466 |  |  |  |  |  |  |  |  |
** | A five-year term commences upon the earliest occurrence of either Trigger Date A or Trigger Date B. Trigger Date A is the date on which the Claimholder ceases the Subject Claim for any reason other than (i) a full and final arbitral award against the Claimholder or (ii) a full and final monetary settlement of the claim, see NOTE 12 Fair Value Financial Instruments – Litigation Financing. Trigger Date B is the date on which Proceeds are deposited into the Escrow Account.
Warrants [Member] |
Fair Value Disclosures [Line Items] |
Summary of Common Stock Warrants Outstanding | The Company’s oustanding and exercisable warrants as of December 31, 2023 are presented below:
Issue Date |  | Exercise Price |  |  | Total Warrants Outstanding |  |  | Exercisable Warrants Outstanding |  |  | Expiration Date |
6/10/2022 |  | $ | 3.35 |  |  |  | 4,848,963 |  |  |  | 4,848,963 |  |  |  | 6/10/2027 |
3/6/2023 |  | $ | 3.78 |  |  |  | 3,703,711 |  |  |  | 3,703,711 |  |  |  | 3/6/2026 |
Various 2020 |  | $ | 3.99 |  |  |  | 551,378 |  |  |  | 551,378 |  |  |  | ** |
12/1/2023 |  | $ | 4.25 |  |  |  | 1,411,769 |  |  |  | 1,411,769 |  |  |  | 12/1/2026 |
8/25/2020 |  | $ | 4.75 |  |  |  | 1,873,622 |  |  |  | 1,873,622 |  |  |  | 2/25/2024 |
7/19/2019 |  | $ | 5.76 |  |  |  | 196,135 |  |  |  | 196,135 |  |  |  | 7/8/2024 |
12/1/2023 |  | $ | 7.09 |  |  |  | 211,570 |  |  |  | 211,570 |  |  |  | 12/1/2026 |
|  |  |  |  |  |  | 12,797,148 |  |  |  | 12,797,148 |  |  |  |  |
** | A five-year exercise period commences upon the earliest occurrence of either Trigger Date A or Trigger Date B. Trigger Date A is the date on which the Claimholder ceases the Subject Claim for any reason other than (i) a full and final arbitral award against the Claimholder or (ii) a full and final monetary settlement of the claim, see Note 12 Fair Value Financial Instruments – Litigation Financing. Trigger Date B is the date on which Proceeds are deposited into the Escrow Account.
Schedule of company's fair value inputs | The Company’s fair value imputs of the warrants as of December 31, 2023 are presented below:
Issue Date |  | Stock price |  |  | Exercise price |  |  | Term in years |  |  | Volitility |  | Treasury Yield |
6/10/2022 |  | $ | 4.65 |  |  | $ | 3.35 |  |  |  | 5 years |  |  | 62.8% |  |  | 3.84 | %
3/6/2023 |  | $ | 4.65 |  |  | $ | 3.78 |  |  |  | 3 years |  |  | 63.7% |  |  | 4.61 | %
12/1/2023 |  | $ | 4.65 |  |  | $ | 4.25 |  |  |  | 3 years |  |  | 58.3%-59.9% |  |  | 4.31 | %
12/1/2023 |  | $ | 4.65 |  |  | $ | 7.09 |  |  |  | 3 years |  |  | 58.3%-59.9% |  |  | 4.31 | %
Derivative liabilities [Member] |
Fair Value Disclosures [Line Items] |
Schedule of company's fair value inputs | The Company’s fair value imputs of derivative liabilities as of December 31, 2023 are presented below:
Issue Date |  | Stock price |  |  | Exercise price |  |  | Term in years |  | Volitility |  |  | Treasury Yield |
6/29/2023 |  | $ | 4.65 |  |  | $ | 3.70 |  |  | 0.75 year |  |  | 59.5 | % |  |  | 5.0 | %
6/4/2023 |  | $ | 4.65 |  |  | $ | 4.40 |  |  | 1 year |  |  | 66.9 | % |  |  | 4.8 | %

X
- References No definition available. + Details
Name: | omex_FairValueDisclosuresLineItems
Namespace Prefix: | omex_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb) -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |